ARROWHEAD PHARMACEUTICALS, INC. (ARWR)
ARROWHEAD PHARMACEUTICALS, INC. (ARWR) is a pharmaceutical company focused on discovering and developing RNA interference (RNAi) and gene therapy solutions for rare diseases, cardiometabolic conditions, and cancers. The company operates in the pharmaceutical biotechnology sector.
What the company does
Arrowhead Pharmaceuticals is a development-stage biopharmaceutical company that discovers and develops therapies based on RNA interference technology and gene therapy. The company’s proprietary platforms allow it to target disease-causing genes at the RNA level, potentially providing treatments for conditions that have limited or no existing therapeutic options. Its pipeline includes programs in hepatology, cardiovascular disease, central nervous system disorders, and oncology.
How it makes money
As a drug development company, Arrowhead’s revenue model centers on the eventual commercialization of FDA-approved therapeutics. The company also generates revenue through research collaborations and licensing agreements with larger pharmaceutical companies. In the development stage, the company relies on capital from equity issuances and partnerships to fund research and clinical trials. Success in advancing candidates through regulatory approval is central to its long-term viability.
Where it sits in its industry
Arrowhead competes in the RNAi and gene therapy space alongside companies pursuing similar nucleotide-based and genetic approaches. The therapeutic targets and development status of its pipeline position it as a company betting on transformative but relatively younger biotechnologies. Many competitors in this space are similarly focused on rare genetic diseases where the addressable market may be smaller but the clinical need is acute and unmet.
How to research it
The company files quarterly and annual reports with the SEC, including its 10-K annual report and 10-Q quarterly reports. These filings detail clinical trial progress, financial condition, and therapeutic pipeline status. For investors, tracking FDA approval milestones, clinical trial results, and cash runway becomes important given the capital-intensive nature of drug development. Patent filings related to its RNAi platform and specific drug candidates offer additional insight into the company’s intellectual property position.